Alunbrig patents expiration

ALUNBRIG's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(7 years from now)

US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors
May, 2029

(5 years from now)

US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(10 years from now)

Alunbrig is owned by Takeda Pharms Usa.

Alunbrig contains Brigatinib.

Alunbrig has a total of 4 drug patents out of which 0 drug patents have expired.

Alunbrig was authorised for market use on 28 April, 2017.

Alunbrig is available in tablet;oral dosage forms.

Alunbrig can be used as treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc).

The generics of Alunbrig are possible to be released after 10 November, 2035.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)


More Information on Dosage

ALUNBRIG family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic